UPDATE 1-Blackstone invests $2 bln in Alnylam, boosting gene-silencing drug development
April 13, 2020 at 08:20 AM EDT
Blackstone Group Inc said on Monday it invested $2 billion in Alnylam Pharmaceuticals Inc through an equity-and-debt deal, giving the drugmaker a financial boost to develop its gene-silencing therapies.
